Previous 10 | Next 10 |
home / stock / trypf / trypf news
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present next week at the H.C. Wainwright Bioconnect Conference and the Biotech Showcase . The event...
Tryp Therapeutics to Participate in Healthcare Conferences in January 2022 Canada NewsWire SAN DIEGO , Jan. 5, 2022 /CNW/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has received information from the U.S. Food and Drug Administration (“FDA”) confirming that the company can proceed w...
Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder Canada NewsWire SAN DIEGO , Dec. 23, 2021 /CNW/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developi...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has reported on corporate updates and filed its audited financial statements for the fiscal year ending August 31, 2021. The c...
Tryp Therapeutics (OTCQB:TRYPF): FY total assets as of August 31, 2021, were C$4.1M, including C$3.7M in cash. Net and comprehensive losses was C$8.3M. Press Release For further details see: Tryp Therapeutics reports FY results
Tryp Therapeutics Announces Fiscal Year 2021 Financial Results and Reports on Corporate Highlights Canada NewsWire SAN DIEGO , Dec. 22, 2021 /CNW/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a pharmaceutical company ...
Tryp just announced FDA confirmation for its IND application filed in November 2021 The confirmation allows the company to proceed with its Phase 2a study on the effectiveness of psilocybin-assisted therapy among patients with fibromyalgia This clinical study will be one of the first ...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is advancing toward the launch of four phase 2a studies of its two novel drug candidates, TRP-8802 and TRP-8803, for treating fibromyalgia, phantom limb pain, complex regional pain syndrome (“CRPS”) and select eating disorders. Try...
Atai Life Sciences (NASDAQ: ATAI) , a clinical-stage biopharmaceutical company whose objective is to transform how mental health conditions are treated, has increased its stake in Compass Pathways. Compass Pathways (NASDAQ: CMPS) is a mental health care company that is focused on improvin...
News, Short Squeeze, Breakout and More Instantly...
Tryp Therapeutics Inc Com Company Name:
TRYPF Stock Symbol:
OTCMKTS Market:
Tryp Therapeutics Inc Com Website:
Kelowna, British Columbia--(Newsfile Corp. - May 17, 2024) - Tryp Therapeutics, Inc. (CSE: TRYP) (" Tryp " or the " Company ") announces, that it has filed amended financial statements for the six months ended February 29, 2024 (the " Financial Statements "), along with the corresponding Manage...
KELOWNA, BC / ACCESSWIRE / May 1, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP, OTCQB: TRYPF ) and Exopharm Limited ACN 163 765 991 (" Exopharm ") are pleased to announce that completion of the previously announced plan of arrangement (the " Arrangement ") effective ...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved...